Complexity of Secretory Chemokines in Human Intestinal Organoid Cultures Ex Vivo.

• Authors: C Cottle, Mercer University School of Medicine; M Anbazhagan, Emory University; A Lipat, Mercer University School of Medicine; M Patel, Mercer University School of Medicine; AP Porter, Mercer University School of Medicine; K Hogan, Mercer University School of Medicine; D Rajan, Mercer University School of Medicine; Jason Matthews, Emory University; Subramaniam Kugathasan, Emory University; R Chinnadurai, Department of Biomedical Sciences, Mercer University School of Medicine, Savannah, Georgia.
• Journal Title: Gastro Hep Adv
• Volume: Volume 1, Number 3
• Publisher: Elsevier Inc | 2022, Pages 457-460
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1016/j.gastha.2022.02.009
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Secretory Chemokines; Crohn’s disease

Abstract

Crohn’s disease (CD) is characterized by chronic inflammation of the mucosa, which involves the release of cytokines and chemokines that promotes further activation and infiltration of leukocytes.1 Leukocyte trafficking to the gut is mediated by the interaction of chemokines with G-protein-coupled receptors, and hence, this interaction can be therapeutically targeted to control mucosal inflammation.2 Despite this therapeutic potential, clinical trials have yet to show efficacy in chemokine-blocking intervention for CD management.3 For example, CCL25 recruits CCR9-expressing leukocytes, and blocking this interaction in a phase III clinical trial with Vercirnon was shown to be ineffective in the treatment of moderate to severe CD.4 This suggests the involvement of more than one chemokine that needs to be targeted in CD management, and the secretory chemokines of intestinal epithelium are unknown. In a recent report, we established an experimental protocol for defining the epithelial secretome in conditioned media of intestinal organoids derived from mucosal biopsies of a pediatric population and showed several interleukins, growth factors, and cytokines released from these cells.5 In the present study, we have extended those findings using the previous technique on non-inflammatory bowel disease (IBD) and CD pediatric patient-derived ileal organoids (IOs) to answer the following questions: (1) What are the different chemokines produced by human ileal epithelium in the absence of in vivo factors? (2) Does ex vivo chemokine secretion from the intestinal epithelium differ in composition or levels between CD and non-IBD individuals? (3) If so, are there any correlations between the levels of chemokines that are secreted by the epithelium?